Health
J&J’s COVID-19 vaccine generates positive pre-clinical results – PMLiVE
Experimental vaccine begins first-in-human trial this month
An experimental vaccine candidate currently being developed by Johnson and Johnson has proved promising in early, pre-clinical studies.
The vaccine, Ad26.COV2.S, induced a robust immune response in monkeys, demonstrated by high levels of neutralising antibodies. According to J&J, this immune response successfully prevented subsequent infection and provided complete or near-complete protection from the SARS-CoV-2 virus, which causes COVID-19.
In the studies, J&J’s researchers initially…
Continue Reading
